DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

DE

465.68

-0.92%↓

CTAS

188.07

-1.24%↓

FDX

288.94

-0.65%↓

HEICO

323.31

-1.38%↓

PAYX

112.17

-1.06%↓

Search

Apogee Enterprises Inc

Slēgts

SektorsRūpniecība

36.35 -1.38

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

36.22

Max

36.88

Galvenie mērījumi

By Trading Economics

Ienākumi

26M

24M

Pārdošana

12M

358M

P/E

Sektora vidējais

18.452

40.202

Dividenžu ienesīgums

2.71

Peļņas marža

6.603

Darbinieki

4,500

EBITDA

26M

45M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+27.37% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.71%

2.12%

Nākamie ieņēmumi

2026. g. 7. janv.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-133M

791M

Iepriekšējā atvēršanas cena

37.73

Iepriekšējā slēgšanas cena

36.35

Ziņu noskaņojums

By Acuity

50%

50%

182 / 454 Rangs Industrials

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Apogee Enterprises Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 31. dec. 22:20 UTC

Galvenie tirgus virzītāji

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025. g. 31. dec. 17:31 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025. g. 31. dec. 16:30 UTC

Galvenie tirgus virzītāji

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025. g. 31. dec. 15:19 UTC

Galvenie tirgus virzītāji

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025. g. 31. dec. 15:17 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025. g. 31. dec. 14:37 UTC

Galvenie tirgus virzītāji

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2025. g. 31. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 31. dec. 21:13 UTC

Iegādes, apvienošanās, pārņemšana

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025. g. 31. dec. 20:40 UTC

Tirgus saruna

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025. g. 31. dec. 20:22 UTC

Tirgus saruna

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025. g. 31. dec. 19:50 UTC

Tirgus saruna

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025. g. 31. dec. 19:31 UTC

Tirgus saruna

Precious Metals Cap Off Record Runs -- Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 31. dec. 18:50 UTC

Tirgus saruna

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025. g. 31. dec. 17:17 UTC

Tirgus saruna

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025. g. 31. dec. 17:16 UTC

Galvenie tirgus virzītāji

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025. g. 31. dec. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 31. dec. 17:00 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025. g. 31. dec. 15:57 UTC

Iegādes, apvienošanās, pārņemšana

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025. g. 31. dec. 15:54 UTC

Tirgus saruna

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025. g. 31. dec. 15:02 UTC

Galvenie tirgus virzītāji

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025. g. 31. dec. 14:40 UTC

Iegādes, apvienošanās, pārņemšana

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025. g. 31. dec. 14:20 UTC

Tirgus saruna

Crude Futures On Track to End the Year With Losses -- Market Talk

2025. g. 31. dec. 13:46 UTC

Tirgus saruna

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

2025. g. 31. dec. 13:01 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

2025. g. 31. dec. 11:10 UTC

Tirgus saruna

Copper Remains in Touching Distance of Record Highs -- Market Talk

2025. g. 31. dec. 10:46 UTC

Tirgus saruna

Euro on Track For Strong Annual Performance -- Market Talk

2025. g. 31. dec. 10:25 UTC

Tirgus saruna

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

2025. g. 31. dec. 10:23 UTC

Tirgus saruna

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

2025. g. 31. dec. 09:33 UTC

Tirgus saruna

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Salīdzinājums

Cenas izmaiņa

Apogee Enterprises Inc Prognoze

Cenas mērķis

By TipRanks

27.37% augšup

Prognoze 12 mēnešiem

Vidējais 47 USD  27.37%

Augstākais 47 USD

Zemākais 47 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Apogee Enterprises Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

40.03 / 40.44Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

182 / 454 Rangs Rūpniecība

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Apogee Enterprises Inc

Apogee Enterprises, Inc. provides architectural products and services for enclosing buildings, and glass and acrylic products used for preservation, protection, and enhanced viewing in the United States, Canada, and Brazil. The company operates in four segments: Architectural Framing Systems, Architectural Glass, Architectural Services, and Large-Scale Optical (LSO). The Architectural Framing Systems segment designs, engineers, fabricates, finishes, and installs custom glass and aluminum window, curtainwall, storefront, and entrance systems for the exterior of buildings primarily in the non-residential construction sectors. The Architectural Glass segment provides a range of high-performance glass products for use in windows, curtainwall, storefront, and entrance systems. The Architectural Services segment integrates technical services, project management, and field installation services to design, engineer, fabricate, and install building glass and curtainwall systems. The LSO segment manufactures high-performance glazing products for the custom framing, fine art, and engineered optics markets. The company's products and services are primarily used in commercial buildings, such as office buildings, hotels, and retail centers; institutional buildings comprising education facilities, health care facilities, and government buildings; transportation facilities, such as airports and transit terminals, as well as multi-family residential buildings. It markets its architectural products and services through direct sales force, independent sales representatives, distributors, and glazing subcontractors and general contractors; and value-added glass and acrylics through retail chains, as well as independent distributors to museums, galleries, and other customers. The company was incorporated in 1949 and is based in Minneapolis, Minnesota.
help-icon Live chat